share_log

Goldman Sachs Initiates Coverage On Tarsus Pharmaceuticals With Neutral Rating, Announces Price Target of $19

Goldman Sachs Initiates Coverage On Tarsus Pharmaceuticals With Neutral Rating, Announces Price Target of $19

高盛以中性评级启动对塔苏斯制药的报道,宣布目标股价为19美元
Benzinga ·  2023/11/20 04:43

Goldman Sachs analyst Andrea Tan initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with a Neutral rating and announces Price Target of $19.

高盛分析师安德里亚·谭以中性评级开始对塔苏斯制药(纳斯达克股票代码:TARS)进行报道,并宣布目标股价为19美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发